Three groups in one experiment
STEP UP randomized 1,407 adults with obesity without diabetes to weekly semaglutide 7.2 mg, semaglutide 2.4 mg or placebo with lifestyle intervention for 72 weeks. It was a double-blind phase 3b study. The higher-dose group was larger than either comparator group. Novo Nordisk funded the trial. [1]
This design provides a direct comparison of the specified regimens within a common study. That is more informative for the dose question than placing numbers from unrelated trials next to each other. It still answers a research question about defined groups, not which regimen a reader should personally use.
Average benefit and tolerability
Using the treatment-policy analysis, weight changed by −18.7% with 7.2 mg, −15.6% with 2.4 mg and −3.9% with placebo. Gastrointestinal adverse events occurred in 70.8%, 61.2% and 42.8%, respectively. Dysaesthesia was reported in 22.9%, 6.0% and 0.5%. [1]
The direct average difference between the active groups was 3.1 percentage points. Presenting that difference beside the adverse-event findings gives a more balanced account than emphasizing only the highest weight-loss percentage. The extra benefit and the reported treatment experience belong in the same discussion.
What the higher number does not establish
This was not a study in which every person taking a lower regimen was switched after a plateau. It therefore should not be presented as a guaranteed additional loss after an individual changes treatment. A randomized group comparison and a personal switching forecast are different propositions.
A published dose comparison also does not, by itself, confirm a current approved indication or the availability of a particular product where a reader lives. Those are separate regulatory and prescribing questions. This article describes the studied intervention and deliberately provides no escalation or administration instructions.
The unequal allocation leaves different amounts of information in each group. Confidence intervals are useful when judging how precise an estimated difference is, especially for less common events. The presence of a large active group should not be taken to mean every safety comparison is equally precise.
Keep the clinical decision individual
Ask the prescriber how the possible benefit, tolerability and current product information apply to your circumstances. A person should not feel that the largest studied dose is automatically the desired destination. The relevant question is the suitability of a treatment plan, not whether it maximizes a number taken from a trial.
Our STEP 5 analysis examines longer follow-up with a different protocol, while the pooled tolerability article explains why symptoms should not be treated as a success measure. Read each source for the particular question it actually investigated.